H. Guchelaar

Publications189
h-index37
Citations5,123
Highly Influential Citations195
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • A. Sparreboom
  • 466 Publications, 25,192 Citations
  • H. McLeod
  • 743 Publications, 35,153 Citations
  • J. Verweij
  • 763 Publications, 63,493 Citations
  • J. Beijnen
  • 1,696 Publications, 58,060 Citations
  • Publications
  • Influence
The risk of cancer in users of statins.
PURPOSE Several preclinical studies suggested a role for 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) in the treatment of cancer. The objective of this study was to compare… Expand
  • 466
  • 17
Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes.
OBJECTIVE To determine associations of methotrexate (MTX) efficacy and toxicity with single-nucleotide polymorphisms (SNPs) in genes coding for folate pathway enzymes in patients with early… Expand
  • 208
  • 12
  • PDF
Genetic Polymorphisms Associated with a Prolonged Progression-Free Survival in Patients with Metastatic Renal Cell Cancer Treated with Sunitinib
Purpose: The objective of this study was to identify genetic polymorphisms related to the pharmacokinetics and pharmacodynamics of sunitinib that are associated with a prolonged progression-free… Expand
  • 144
  • 12
  • PDF
Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer.
Statins (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors - HMG-CoA reductase inhibitors) have been approved for the treatment of lipid disorders. Recently, in vivo studies with… Expand
  • 274
  • 11
  • PDF
A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis.
OBJECTIVE To develop a clinical pharmacogenetic model to predict the efficacy of methotrexate (MTX) in rheumatoid arthritis (RA). METHODS Two hundred five patients with newly diagnosed RA and… Expand
  • 228
  • 11
Relationship between Single Nucleotide Polymorphisms and Haplotypes in DPYD and Toxicity and Efficacy of Capecitabine in Advanced Colorectal Cancer
Purpose: To explore the effect of dihydropyrimidine dehydrogenase (DPD) single nucleotide polymorphisms (SNP) and haplotypes on outcome of capecitabine. Experimental Design: Germline DNA was… Expand
  • 147
  • 6
  • PDF
Glutathione S-transferase Polymorphisms Are Not Associated With Population Pharmacokinetic Parameters of Busulfan in Pediatric Patients
High busulfan exposure is associated with increased toxicity, for example veno-occlusive disease, whereas low exposure results in less efficacy such as lower engraftment rates. Despite adjusting dose… Expand
  • 69
  • 6
Cardiotoxicity of cytotoxic drugs.
Cardiotoxicity is a well-known side effect of several cytotoxic drugs, especially of the anthracyclines and can lead to long term morbidity. The mechanism of anthracycline induced cardiotoxicity… Expand
  • 339
  • 5
Translating Pharmacogenomics: Challenges on the Road to the Clinic
Pharmacogenomics is one of the first clinical applications of the postgenomic era. It promises personalized medicine rather than the established “one size fits all” approach to drugs and dosages. The… Expand
  • 163
  • 5
  • PDF
A systematic review on pharmacogenetics in cardiovascular disease: is it ready for clinical application?
Pharmacogenetics is the search for heritable genetic polymorphisms that influence responses to drug therapy. The most important application of pharmacogenetics is to guide choosing agents with the… Expand
  • 73
  • 5
  • PDF